Pharmaceutical - Antibiotics and Infectious diseases


Popular Filters

176 to 200 of 210 results

ViroPharma stock plunges on bad news for Vancocin; Sanofi patents invalidated


ViroPharma I (Nasdaq: VPHM) saw its shares plunge 19% to $23.25 yesterday after it announced that the…

Antibiotics and Infectious diseasesApotexGenericsHospiraLegalNorth AmericaOncologyPatentsPharmaceuticalRegulationSanofiTaxotereVancocinViroPharmaWatson Pharmaceuticals

Optimer Pharma could earn $90 million from new Astellas deal


US firm Optimer Pharmaceuticals (Nasdaq: OPTR) has entered into a second deal with Japanese drug major…

Antibiotics and Infectious diseasesAsia-PacificAstellas PharmaDificidfidaxomicinLicensingOptimer PharmaceuticalsPharmaceutical

New pathway proposed for antibiotic approval in USA


The US Congress will consider a new drug approval pathway to encourage development of critically needed,…

Antibiotics and Infectious diseasesNorth AmericaPharmaceuticalRegulationResearch

Daiichi Sankyo and Terumo link up for vaccine development


Drug major Daiichi Sankyo (TYO: 4568) and fellow Japanese company Terumo Corp (TYO: 4543) have entered…

Antibiotics and Infectious diseasesDaiichi SankyoPharmaceuticalResearchTerumoVaccines

Additional indications in Japan for Diagnogreen and Sawacillin


Japanese drug major Daiichi Sankyo (TYO: 4568) says it has received approval in Japan for a supplemental…

Antibiotics and Infectious diseasesAsia-PacificAstellas PharmaDaiichi SankyoPharmaceuticalRegulationSawacillin

Hospira challenges Cubist patents on Cubicin


US drugmaker Cubist Pharmaceuticals (Nasdaq: CBST) says that it has received a Paragraph IV Notice Letter…

Antibiotics and Infectious diseasesCubicinCubist PharmaceuticalsGenericsHospiraNorth AmericaPatentsPharmaceuticalResearch

GlaxoSmithKline pauses four UTI drug trials


UK pharma giant GlaxoSmithKline (LSE: GSK) has voluntarily paused enrollment in its current clinical…

Anacor PharmaceuticalAntibiotics and Infectious diseasesGlaxoSmithKlinePharmaceuticalResearch

Sanofi Pasteur and Vivalis extend MAb accord


French biopharma company Vivalis (NYSE Euronext: VLS) says it has extended the agreement signed in 2010…

Antibiotics and Infectious diseasesLicensingPharmaceuticalResearchSanofiSanofi PasteurVivalis

Licensing deal for Basilea in sight


The completion of the pneumonia data audit and confirmation of the timeline for Switzerland-based Basilea’s…

Antibiotics and Infectious diseasesBasilea PharmaceuticaceftobiproleDermatologicalsLicensingPharmaceuticalResearchToctino

Astellas pulls out of deal with Theravance


Japanese drug major Astellas Pharma (TYO: 4503) says it has exercised its right to terminate the global…

Antibiotics and Infectious diseasesAstellas PharmaLicensingPharmaceuticalTheravanceVibativ

European Medicines Agency releases adverse reaction report


European Ombudsman Nikiforos Diamandouros has welcomed the European Medicines Agency's release of adverse…

Antibiotics and Infectious diseasesEuropePharmaceuticalRegulation

Astellas and Optimer’s C. difficile drug cleared in Europe


Following an earlier positive recommendation from a European Medicines Agency advisory panel (The Pharma…

Antibiotics and Infectious diseasesAstellas PharmaDificidDificlirEuropeOptimer PharmaceuticalsPharmaceuticalRegulation

TaiGen gets global nemonoxacin rights


Taiwan’s TaiGen Biotechnology has reached a deal with Ireland-headquartered Warner Chilcott (Nasdaq:…

Antibiotics and Infectious diseasesBiotechnologyLicensingnemonoxacinPharmaceuticalTaiGen BiotecnologyWarner Chilcott

Backing for Japanese approval of Regnite, Ranmark and Cancidas


USA-based XenoPort (Nasdaq: XNPT) saw its shares rise 3% to $4.73 on Friday, when the company said it…

Antibiotics and Infectious diseasesAsia-PacificCancidasDaiichi SankyodenosumabHorizantMerck & CoOncologyPharmaceuticalRegniteRegulationXenoPort

New compound defeats drug-resistant bacteria


Bacteria can use efflux pumps to rid themselves of antibiotics, becoming drug-resistant until newer antibiotics…

Antibiotics and Infectious diseasesMPEX PharmaceuticalsPharmaceuticalResearch

World antibacterials market to grow to $43.8 billion in 2016, says Visiongain


World revenues for antibacterial drugs will reach $43.81 billion in 2016. Between 2010 and 2022, the…

Antibiotics and Infectious diseasesGlobalMarkets & MarketingPharmaceutical

Key hospital-infections markets set to grow to over $4 billion in 2020; report


Despite market constraints that include intensified competition, generic erosion and an increasingly…

Antibiotics and Infectious diseasesGlobalMarkets & MarketingPharmaceutical

EU Commission unveils 12 concrete actions against antimicrobial resistance for the next five years


With about 25,000 patients dying per year in the European Union from infections caused by drug resistant…

Antibiotics and Infectious diseasesEuropePharmaceuticalRegulationResearch

Sanofi Pasteur and CureVac collaborate on a $33.1 million project on vaccines for infectious diseases


Germany’s CureVac says it has signed several agreements with Sanofi Pasteur, the vaccines division…

Antibiotics and Infectious diseasesBiotechnologyCureVacLicensingPharmaceuticalResearchSanofiSanofi PasteurVaccines

US hospital pharmacy and therapeutics committees decision-making process for antibiotics and antifungal therapies


In addition to managing the hospital’s anti-infective formulary, hospital pharmacy and therapeutics…

Antibiotics and Infectious diseasesGenericsMarkets & MarketingNorth AmericaPharmaceutical

US FDA should require Black Box warning for Pfizer’s antibiotic Tygacil, says Public Citizen


US advocacy group Public Citizen has sent a petition to the Food and Drug Administration calling on the…

Antibiotics and Infectious diseasesNorth AmericaPfizerPharmaceuticalRegulationTygacil

EFPIA supports a new R&D model to tackle antimicrobial resistance


A vote of the European Parliament’s Health Committee on the threat posed by antimicrobial resistance,…

Antibiotics and Infectious diseasesEuropePharmaceuticalPoliticsResearch

Eli Lilly pulls sepsis drug Xigris off all markets, due to lack of efficacy


US drug major Eli Lilly (NYSE: LLY) revealed yesterday that it is withdrawing its Xigris (drotrecogin…

Antibiotics and Infectious diseasesEli LillyMarkets & MarketingPharmaceuticalResearchXigris

GlaxoSmithKline warned by US FDA over cGMP violations at UK plant; positive malaria vaccine news


UK pharma giant GlaxoSmithKline ILSE: GSK) has received a warning letter from the US Food and Drug Administration…

Antibiotics and Infectious diseasesGlaxoSmithKlinePharmaceuticalRegulationResearchVaccines

176 to 200 of 210 results

Back to top